Xlife Sciences AG Shareholders Endorse Strategic Milestones Including Veraxa Biotech Nasdaq Listing and Planned Landsteiner Scientific Platform
Found this article helpful?
Share it with your network and spread the knowledge!
Xlife Sciences AG (SIX: XLS) announced that shareholders approved all proposals presented at the company’s Annual General Meeting, where 3,134,367 voting shares, representing 54.3% of the total share capital, were represented. Chairman David L. Deck said the company strengthened its portfolio during the past year and highlighted the Nasdaq listing of portfolio company Veraxa Biotech (NASDAQ: VRXA) and the planned Landsteiner Scientific platform as key milestones supporting the next phase of growth.
The company also emphasized the strategic importance of the planned Landsteiner Scientific platform, which is intended to accelerate the identification and development of novel therapeutic approaches while improving global market access for Xlife Sciences’ portfolio companies. Management said the platform will integrate academic research with commercial development and serve as a cornerstone of the company’s future innovation pipeline, while also outlining upcoming capital markets activities. For more details, visit the full press release at https://ibn.fm/nfUvM.
Xlife Sciences is a Swiss company focused as incubator and accelerator on the value development and commercialization of promising research projects from universities and other research institutions in the life sciences sector, with the aim of providing solutions for high unmet medical needs and a better quality of life. The goal is to bridge research and development to healthcare markets. Xlife Sciences takes carefully selected projects in the four areas of technological platforms, biotechnology/therapies, medical technology, and artificial intelligence/digital health to the next stage of development and participates in their subsequent performance. For more information, visit www.xlifesciences.ch.
This shareholder approval solidifies the company’s strategic direction and underscores the potential economic impact of its portfolio companies, particularly in Texas where the life sciences sector continues to grow. The planned Landsteiner Scientific platform could streamline the path from academic research to commercial therapies, benefiting patients and investors alike.